Tissue non-sterility fears hit Osteotech as CryoLife toes FDA line
This article was originally published in Clinica
Executive Summary
Eatontown, New Jersey-based tissue provider Osteotech has withdrawn sales estimates of up to $93.5m for 2002 following its suspension of some production this week. The company said it was initiating a voluntary recall of tissue, gathered from 15 donors whose tissue was processed and shipped by Osteotech to two clients, following higher-than-normal sterility failures in finished products.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.